Theralase Technologies Inc.  

(Public, CVE:TLT)   Watch this stock  
Find more results for TLT
+0.015 (4.92%)
Delayed:   9:41AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.32 - 0.32
52 week 0.25 - 0.78
Open 0.32
Vol / Avg. 28,600.00/184,262.00
Mkt cap 33.71M
P/E     -
Div/yield     -
EPS -0.04
Shares 104.65M
Beta 1.84
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -253.50% -187.42%
Operating margin -253.50% -187.42%
EBITD margin - -180.94%
Return on average assets -53.56% -79.59%
Return on average equity -57.62% -102.09%
CDP Score - -


1945 Queen Street East
+1-416-6995273 (Phone)
+1-416-6995250 (Fax)

Website links


Theralase Technologies Inc. is a Canada-based designer, developer and manufacturer of super-pulsed, cold laser technology. It provides its technology to a range of human, companion animal and equine applications. Bio-stimulative capabilities of the Company’s laser systems include healing neural muscular skeletal conditions through pain elimination, inflammation reduction and increased tissue regeneration. In addition to the development and provision of laser technology, the Company operates a full service medical rehabilitation clinic in Toronto, Ontario for training and education of health-care practitioners. It is investigating the use of Photo Dynamic Compounds (PCD) molecules in the destruction of cancer cells.

Officers and directors

S. Donald Donald Moore Chairman of the Board
Roger Dumoulin-White President, Chief Executive Officer, Director
Kristina Hachey Chief Financial Officer
Michael Borovec Director of Investor Relations
Matthew Perraton Director
Guy John Anderson Independent Director
Age: 1
Randall Bruder Independent Director